.jpeg)
{{ variable.name }}
Ixazomib is an oral, highly selective proteasome inhibitor. By inhibiting the proteasome function in cells, it blocks the normal metabolism and decomposition mechanism of cancer cells, causing the death of cancer cells.
1. Generic name:Ixazomib (Ixazomib)
2. Trade name:NINLARO®
1. In combination with lenalidomide and dexamethasone, it is used to treat patients with multiple myeloma who have received at least one previous therapy.
2. Not recommended for maintenance treatment or newly diagnosed multiple myeloma (unless in controlled clinical trials).
Capsule specifications: 4mg
1. Active ingredient: ixazomib (ixazomib)
2. Excipients: Microcrystalline cellulose, magnesium stearate, talc, etc.
1. Standard dosage: Once a week, 4 mg each time, orally on days 1, 8, and 15 of a 28-day treatment cycle.
2. Combined medication: Lenalidomide (25 mg/day, days 1-21) and dexamethasone (40 mg, days 1, 8, 15, and 22) need to be taken at the same time.
3. Taking time: It needs to be taken on an empty stomach, at least 1 hour before a meal or at least 2 hours after a meal.
1. Liver injury : The starting dose of is reduced to 3mg for patients with moderate to severe liver injury.
2. Renal impairment : For patients with severe renal impairment or those requiring dialysis, the starting dose is reduced to 3 mg.
3. Adverse reaction adjustment :
Plateletopenia (<30,000/mm³) or neutropenia (<500/mm³): suspend the medication and reduce the dose after recovery.
4. Peripheral neuropathy (≥Grade 2 with pain): Reduce the dose or discontinue the drug.
5. Rash (≥Grade 2):Adjust dosage or discontinue medication.
1. How to take : Swallow the capsule whole. Do not crush, chew or open the capsule.
2. Treatment of missed doses : If it is ≥ 72 hours before the next dose, you can take it again, otherwise skip it.
3. Post-vomiting treatment : No need to take additional doses, just take the next dose as originally planned.
4. Avoid taking with dexamethasone: Because dexamethasone needs to be taken with food, while ixazomib needs to be taken on an empty stomach.
1. Pregnant women : may cause fetal damage, so contraception is required until 90 days after the last dose.
2. Lactation : Breastfeeding is prohibited during treatment and within 90 days after the last dose.
3. Children : The safety and effectiveness have not been established.
1. Common (≥20%): Thrombocytopenia, neutropenia, diarrhea, constipation, peripheral neuropathy, nausea, peripheral edema, rash, vomiting, bronchitis.
2. Serious adverse reactions: Thrombotic microangiopathy, Stevens-Johnson syndrome, hepatotoxicity, etc.
There are no clear contraindications, but you need to be wary of allergic reactions.
Avoid co-administration with strong CYP3A inducers (such as rifampicin, phenytoin), which may reduce the efficacy of ixazomib.
Save at room temperature (≤30°C), do not freeze.
Keep the original packaging until before taking, and avoid direct contact with the contents of the capsule.